Takhzyro denied as experimental or investigational by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for takhzyro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Deny Takhzyro as Experimental — and Why This Is Wrong

A denial of Takhzyro (lanadelumab) as "experimental" or "investigational" is factually incorrect for its FDA-approved indication: prophylaxis to prevent HAE attacks in adults and adolescents with hereditary angioedema. Takhzyro received full FDA approval and has been on the U.S. market. An experimental denial almost always means the claim was filed under a diagnosis code that UHC's system did not match to the approved indication, or the plan's policy has not been updated to reflect current approval status.

This is a strong basis for appeal. FDA approval is a matter of public record and the insurer cannot override it by labeling an approved drug experimental.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 entitle you to internal appeal and independent external review.
• File your internal appeal within 180 days of the denial.
• External review window: approximately 4 months after final internal denial.
• Expedited review is appropriate if you are at elevated risk of a life-threatening angioedema attack — laryngeal attacks can be fatal.

## Appeal Timeline

1. Obtain the denial letter and the specific language UHC used to define "experimental" in its policy. 2. Pull the FDA approval letter and current product label from DailyMed. 3. File a written internal appeal citing FDA approval and attaching the label. 4. If denied internally, proceed to external IRO — IROs consistently overturn experimental denials for FDA-approved drugs used on-label.

## Documentation to Gather

• FDA approval evidence: Printout of the current FDA-approved label from DailyMed (dailymed.nlm.nih.gov) showing the approved indication.
• Diagnosis confirmation: Lab or genetic confirmation of HAE matching the approved indication.
• Prescriber letter: Explicit statement that Takhzyro is being prescribed for its FDA-approved indication, not off-label.
• Clinical severity: Attack history demonstrating the need for prophylactic therapy.
• Denial policy language: The exact UHC policy definition of "experimental" — most definitions exclude FDA-approved drugs used on-label by design.

## Criteria-Mapping Structure

| Experimental-Denial Requirement | Response | |---|---| | Drug lacks FDA approval | FDA approval letter / DailyMed label | | Use is off-label | Prescriber attestation of on-label use | | Lacks adequate clinical evidence | Published guideline organization support (e.g., applicable US Hereditary Angioedema Association guidance) |

Obtain UHC's current coverage policy for Takhzyro (request from UHC member services or find on UHC's provider portal) and compare its experimental-criteria definition line by line against the FDA record. That comparison is the core of your appeal.